184 related articles for article (PubMed ID: 35981396)
1. [Clinical Safety of NK Cell in the Prevention of Leukemia Relapse Post-transplantation and in Treatment of the Elderly Leukemia Patients].
Liu J; Zheng XL; Xue M; Zhu L; Ding L; Han DM; Yan HM; Li S; Ma JD; Tan XT; Zhou JX; Guo ZK; Wang HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1267-1271. PubMed ID: 35981396
[TBL] [Abstract][Full Text] [Related]
2. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
3. Case report: Donor-derived CLL-1 chimeric antigen receptor T-cell therapy for relapsed/refractory acute myeloid leukemia bridging to allogeneic hematopoietic stem cell transplantation after remission.
Miao X; Shuai Y; Han Y; Zhang N; Liu Y; Yao H; Wang X; He G; Chen D; Fan F; Chang AH; Su Y; Yi H
Front Immunol; 2024; 15():1389227. PubMed ID: 38803489
[TBL] [Abstract][Full Text] [Related]
4. Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation.
Shaffer BC; Le Luduec JB; Forlenza C; Jakubowski AA; Perales MA; Young JW; Hsu KC
Biol Blood Marrow Transplant; 2016 Apr; 22(4):705-709. PubMed ID: 26772158
[TBL] [Abstract][Full Text] [Related]
5. [Observation on the efficacy of consolidation chemotherapy combined with allogeneic natural killer cell infusion in the treatment of low and moderate risk acute myeloid leukemia].
Wang CJ; Huang XJ; Gong LZ; Jia JS; Liu XH; Wang Y; Yan CH; Chang YJ; Zhao XS; Shi HX; Lai YY; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):812-817. PubMed ID: 31775478
[No Abstract] [Full Text] [Related]
6. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
[TBL] [Abstract][Full Text] [Related]
7. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
[TBL] [Abstract][Full Text] [Related]
8. [The Relationship between Occurrence of aGVHD in Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation and Immune Cell Components in Graft].
Liu S; Zhou Z; Zhai WJ; Song XN; Li Q; Jiang EL; Feng SZ; Sun JL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):539-545. PubMed ID: 37096531
[TBL] [Abstract][Full Text] [Related]
9. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
[TBL] [Abstract][Full Text] [Related]
10. [Clinical observation of 12 patients with refractory/relapsed acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation containing cladribine regimen].
Ai H; Fu YW; Wang YQ; Wei XD; Song YP
Zhonghua Xue Ye Xue Za Zhi; 2019 Oct; 40(10):827-830. PubMed ID: 31775481
[No Abstract] [Full Text] [Related]
11. Impact of natural killer cells on outcomes after allogeneic hematopoietic stem cell transplantation: A systematic review and meta-analysis.
Mushtaq MU; Shahzad M; Shah AY; Chaudhary SG; Zafar MU; Anwar I; Neupane K; Khalid A; Ahmed N; Bansal R; Balusu R; Singh AK; Abhyankar SH; Callander NS; Hematti P; McGuirk JP
Front Immunol; 2022; 13():1005031. PubMed ID: 36263054
[TBL] [Abstract][Full Text] [Related]
12. Azacitidine and lenalidomide combination: a novel relapse prophylaxis regimen after allogeneic hematopoietic stem-cell transplantation in patients with acute myeloid leukemia.
Feng Y; Chen T; Zhang Y; Yao H; Wang P; Wang L; Cassady K; Zou Z; Liu Y; Zhao L; Gao L; Zhang X; Kong P
Front Immunol; 2023; 14():1182251. PubMed ID: 37435080
[TBL] [Abstract][Full Text] [Related]
13. How important is NK alloreactivity and KIR in allogeneic transplantation?
Shaffer BC; Hsu KC
Best Pract Res Clin Haematol; 2016 Dec; 29(4):351-358. PubMed ID: 27890259
[TBL] [Abstract][Full Text] [Related]
14. Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.
Curti A; Ruggeri L; D'Addio A; Bontadini A; Dan E; Motta MR; Trabanelli S; Giudice V; Urbani E; Martinelli G; Paolini S; Fruet F; Isidori A; Parisi S; Bandini G; Baccarani M; Velardi A; Lemoli RM
Blood; 2011 Sep; 118(12):3273-9. PubMed ID: 21791425
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stem cells enhance the impact of KIR receptor-ligand mismatching on acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia but not in those with acute lymphocytic leukemia.
Zhang Y; Zheng H; Ren J; Luo X; Zheng Z; Zheng J; Zheng X; Chen Y; Chen Z; Hu J; Yang T
Hematol Oncol; 2021 Aug; 39(3):380-389. PubMed ID: 33848027
[TBL] [Abstract][Full Text] [Related]
16. HLA-Matched Sibling versus Unrelated versus Haploidentical Related Donor Allogeneic Hematopoietic Stem Cell Transplantation for Patients Aged Over 60 Years with Acute Myeloid Leukemia: A Single-Center Donor Comparison.
Devillier R; Legrand F; Rey J; Castagna L; Fürst S; Granata A; Charbonnier A; Harbi S; d'Incan E; Pagliardini T; Faucher C; Lemarie C; Saillard C; Calmels B; Mohty B; Maisano V; Weiller PJ; Chabannon C; Vey N; Blaise D
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1449-1454. PubMed ID: 29448057
[TBL] [Abstract][Full Text] [Related]
17. [Comparison of the characteristics of NK cells after two different methods of expansion and observation of the clinical efficacy in patients who relapsed post allogeneic hematopoietic stem cell transplantation].
Cao XH; Wang ZD; Sun YQ; Kong J; Lu SY; Tang FF; Zhang YY; Wang JZ; Xu LP; Zhang XH; Wang Y; Liu KY; Huang XJ; Zhao XY
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):400-407. PubMed ID: 35680598
[No Abstract] [Full Text] [Related]
18. Comparable outcomes among unmanipulated haploidentical, matched unrelated, and matched sibling donors in BU-based myeloablative hematopoietic stem cell transplantation for intermediate and adverse risk acute myeloid leukemia in complete remission: a single-center study.
Lu Y; Zhao YL; Zhang JP; Xiong M; Cao XY; Liu DY; Sun RJ; Wei ZJ; Zhou JR; Lu DP
Ann Hematol; 2021 Jun; 100(6):1579-1591. PubMed ID: 33236196
[TBL] [Abstract][Full Text] [Related]
19. Transformation of Severe Aplastic Anemia into Donor Cell Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Rare Case Report.
Wang Q; Xu H; Yu W; Sun L; Zhao H; Shi X
Am J Case Rep; 2024 Apr; 25():e943801. PubMed ID: 38632857
[TBL] [Abstract][Full Text] [Related]
20. [Donor peripheral hematopoietic stem cells infusion for prophylaxis of relapse of high risk leukemia after allogeneic hematopoietic stem cell transplantation].
Liu DH; Huang XJ; Chen H; Xu LP; Liu KY; Han W; Lu DP
Zhonghua Xue Ye Xue Za Zhi; 2006 Jan; 27(1):6-9. PubMed ID: 16732930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
